A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. 1988

E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
Postgraduate School of Hematology Farreras Valentí, University of Barcelona, Hospital Clinic, Spain.

Ninety-six previously untreated patients (67 males/29 females; mean age: 63 years; range: 46-84) with CLL in stage B (62 cases) or C (34 cases) were randomized to be treated with either chlorambucil (0.4 mg/kg orally days 5 and 6) plus prednisone (60 mg/m2 orally days 1 to 4) (CL + PDN) every 2 weeks or cyclophosphamide (160 mg/m2 orally days 1 to 4), melphalan (6 mg/m2 orally days 1 to 4), and prednisone (60 mg/m2 orally days 1 to 4) (CMP) every 3 weeks for 10 months. Forty-eight patients were treated with CLR + PDN, and the remaining 48 with CMP. The following types of response were considered: complete response (CR): total disappearance of symptoms and signs related to the disease. Partial response (PR): shift of the disease to a less advanced stage. Stable disease (SD) no change in the stage after treatment. Progressive disease (PD): progression of the disease to a more advanced stage. Thirty-six (75%) responses (27% CR) with CLR + PDN and 26 (54.5%, 12.5% CR) with CMP were observed (p = 0.054). Although more responses were achieved in stage B (69%, 24% CR) than in stage C (54%, 12% CR) this difference did not achieve statistical significance. Survival was statistically not different for those patients treated with LCR + PDN as compared to those receiving CMP.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002699 Chlorambucil A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed) 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid,Amboclorin,CB-1348,Chloraminophene,Chlorbutin,Leukeran,Lympholysin,N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid,NSC-3088,CB 1348,CB1348,NSC 3088,NSC3088
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females

Related Publications

E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
January 1991, Leukemia & lymphoma,
E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
January 1991, Leukemia & lymphoma,
E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
January 1988, Nouvelle revue francaise d'hematologie,
E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
January 1988, Nouvelle revue francaise d'hematologie,
E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
April 1990, Blood,
E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
March 1973, Cancer,
E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
January 1985, Oncology,
E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
May 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
August 1989, Cancer,
E Montserrat, and A Alcalá, and C Alonso, and J Besalduch, and J M Moraleda, and J García-Conde, and M Gutierrez, and F Gomis, and J Garijo, and M C Guzmán
July 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!